All procedures were in accordance with the US National Institutes of Health (NIH) guidelines for the care and use of laboratory animals and were approved by ...
The European panel has expanded delivery options for multiple myeloma by approving a subcutaneous (SC) option for a key anti‑CD38 myeloma therapy. At its March 2026 meeting, the European Medicines ...
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating ...
The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits. The U.S. Food and Drug Administration (FDA) has approved a new once ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing with Johnson & Johnson’s powerhouse Darzalex, largely because it reached ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results